

Q2 FY23 Quarterly Investor Presentation

Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to provide its Q2 FY23 Investor Presentation to be delivered at the Quarterly Investor Webinar held today with CEO Dr Luke Reid at 10:30am AEDT (Sydney/Melbourne) / 9:30am AEST (Brisbane).

Presenting: Microba CEO, Dr Luke Reid

Time: 10:30am AEDT (Sydney/Melbourne) / 9:30am AEST (Brisbane) on Tuesday, 31 January 2023

To register for the Quarterly Investor Webinar please click the link below. Investors can submit questions prior to the webinar to simon@nwrcommunications.com.au or do so via the Q&A function during the webinar.

[Register for the Investor Webinar here](#)

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

MICROBA™

Transforming health through the human microbiome

January 2023 | *Authorised for release by the CEO & Chairman*

Disclaimer

This presentation (**Presentation**) has been prepared by Microba Life Sciences Limited (**Microba**).

Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the *Corporations Act 2001* (Cth) (**Corporations Act**).

Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above.

Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs. This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended.


Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise.

Financial data – All dollar values in Australian dollars (A\$ or \$) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba's views on its future financial condition and/or performance.

Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright.

Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation.

Two core business segments driven by a proprietary databank



Company Snapshot



Continuous YoY revenue growth over 5 years of operations



Partnerships with market leaders incl. **SYNLAB** (GR:SYAB), **Sonic Healthcare** (ASX: SHL), **Genova Diagnostics**, and **G42**



Large, unique, proprietary microbiome databank



3 key therapeutic programs with lead IBD drug candidate **progressing to Phase 1 trial**



World-leading technology in the emerging **US\$4.89 billion** microbiome sector¹



Globally **leading microbiome expertise** complemented by drug discovery experts including Prof. Ian Frazer

Microbiome Services

Driving global revenues
and data growth

Testing Services - Key Q2 FY23 Milestones



STRATEGIC INVESTMENT & PARTNERSHIP

Positive progress in distribution relationship with Sonic federation companies. Stage 1 Germany and Australia.



ITALY & PORTUGAL SIGNED & COMMENCED

Signed, commenced and first sales already achieved in Italy and Portugal



NEW HEALTHCARE PRODUCT

Full launch date now scheduled for Feb 2023.

Microba's leading international bench of healthcare partners



\$9.3bn Revenue
Partnership: UK, Germany, Belgium, Australia, US, NZ & Switzerland



\$5.8bn Revenue
Partnership: Europe & LATAM




Leading GI Diagnostics in US
Partnership: US



Raised USD \$800m
Partnership: GCC Region

Microba's **Healthcare & Pathology Partners**

Significant international distribution expansion for Microba's testing services




Access into
35 countries

Operations **only**
activated in **7**
of 35 countries

Significant growth
prospects ahead

Accelerating expansion and adoption



Leading bench of healthcare partners provides access into 35 countries

Staged rollout to be executed to ensure market success

New regions to operationalise in FY23 are in focus.

Sonic expected to impact revenue from FY24

Sonic Healthcare – Global Distribution Partnership

Stage 1 - Germany and Australia distribution

- Sonic federation company engagement progressing well
- Staged approach
 - Stage 1 – Germany & Australia
 - Stage 2 – Additional countries
- Impact to revenues expected FY24



- Founded in 1934
- **\$16B market cap** - second largest healthcare company on ASX
- **\$9.3B in revenues** in FY22
- **Employs more than 41,000** people globally
- 7 major markets – Australia, United Kingdom, United States, Germany, Belgium, Switzerland

SYNLAB – Europe & LATAM Distribution Partnership

Country expansion




- Founded 1998
- **Europe's largest** medical diagnostics provider
- **\$5.7B** in revenues in FY22
- **Employs around 30,000** people globally
- Operates in 36 countries across four continents

- **Italy & Portugal signed**
- **Italy important territory – 3rd largest probiotics market in the world**
- **First sales already achieved in both regions**

Microbiome Therapeutics

Developing novel monoclonal
microbial cell therapies

Repeatable, scalable, data-driven platform **discovering novel monoclonal microbial cell therapies**



Proprietary microbiome databank driving **multiple therapeutic opportunities through a capital light platform**

Therapeutics - Key Q2 FY23 Milestones



MANUFACTURING THROUGH TO DRUG PRODUCT

MAP 315 engineering production through to full encapsulated drug product.



Image: MAP 315 capsules at Bacthera



FDA PRE-IND MEETING POSITIVE OUTCOME

- Positive formal feedback from the FDA on Pre-IND briefing book and pre-clinical package.
- Supports upcoming HREC submission for Phase 1 study initiation.
- Supports roadmap to a global Phase II study for MAP 315.



Key milestones executed advancing to first in human clinical trial

Inflammatory Bowel Disease



PROGRESSING TO PHASE I

Recently Completed

- ✓ Manufacturing scale up
- ✓ FDA Pre-IND meeting requested
- ✓ FDA Pre-IND meeting outcome

Upcoming milestones

- Phase 1 HREC submission
- Phase 1 HREC approval
- cGMP manufacturing complete
- Phase 1 trial commencement



Cancer Immunotherapy



PRECLINICAL

Recently Completed

- ✓ Leads discovered
- ✓ Leads isolated

Upcoming milestones

- First animal model results
- Immunological MOA studies



Autoimmune Diseases



SCREENING

Recently Completed

- ✓ Program commenced
- ✓ Strains provided to Ginkgo

Upcoming milestones

- First in vitro screening results



The start of a therapeutic revolution



APPROVED 30 Nov 2022
Fecal doner derived enema
drug product



**26 April PDUFA date for
anticipated FDA approval**
Fecal doner derived oral
capsule drug product



**RECENT FDA APPROVAL HAS
CLEARED THE PATH TO MARKET
FOR LIVE MICROBIOME DRUGS,
A NEW MODALITY.**

First Generation
Fecal Doner Derived



Second Generation
Bacterial Consortia



Next Generation
Single Strain & Small Molecule



Outlook



Upcoming Milestones for FY23

2023 JAN - MAR	2023 APR - JUN
<p>Services New healthcare product full launch</p>	
<p>Services New international distribution deals</p>	
<p>Therapeutics - IBD MAP315 program Phase 1 HREC Submission</p>	
<p>Therapeutics - IBD MAP315 program FDA Pre-IND meeting outcome</p>	
<p>Therapeutics - IO Program Pre-clinical results</p>	<p>Services New international distribution deals</p>
<p>Therapeutics – Autoimmune Program First <i>in vitro</i> screening results</p>	<p>Therapeutics - IBD MAP315 program GMP manufacture complete for Ph1</p>
	<p>Therapeutics - IBD MAP315 program HREC Approval for Phase 1 trial</p>
	<p>Therapeutics - IBD MAP315 program Phase 1 trial commencement</p>

Contact



Dr Luke Reid

Chief Executive Officer
luke.reid@microba.com



Pasquale Rombola

Chairman
pasquale.rombola@microba.com

Head Office

Level 10, 324 Queen Street
Brisbane QLD Australia

Laboratory

Princess Alexandra Hospital
Woolloongabba QLD Australia